Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer

Mok T.Ladrera G.Srimuninnimit V.Sriuranpong V.CHONG-JEN YUThongprasert S.Sandoval-Tan J.Lee J.S.Fuerte F.Shames D.S.Klughammer B.Truman M.Perez-Moreno P.Wu Y.-L.2022-06-272022-06-2720160169-5002https://www.scopus.com/inward/record.uri?eid=2-s2.0-84966701371&doi=10.1016%2fj.lungcan.2016.04.023&partnerID=40&md5=a3db97d14c964d54437c5d15f284547dhttps://scholars.lib.ntu.edu.tw/handle/123456789/614132[SDGs]SDG3Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancerjournal article10.1016/j.lungcan.2016.04.023273934992-s2.0-84966701371